DTC meeting planned
This article was originally published in The Gray Sheet
FDA plans to hold a public hearing on direct-to-consumer promotion of medical products, including medical devices, Nov. 1-2 in Washington, D.C. "Medical device DTC promotion has not yet received as much FDA attention because, until recently, there has not been a significant amount of DTC device promotion," the agency notes in a Sept. 13 Federal Register notice. FDA points to "recent increases in DTC device promotion and a growing awareness among consumers that medical devices may give them important choices." Those interested in participating must contact FDA by Oct. 11...
You may also be interested in...
Firms providing access to independent websites should provide the links on centralized corporate pages rather than on product-specific Internet sites, FDA's Office of Compliance staffer Deborah Wolf suggested Sept. 20
Public Company Edition: Lixte’s small uplisting was the only biopharma initial public offering in the US during Thanksgiving week, but IPOs are ramping up again. Also, LifeSci launched its second SPAC and in follow-on offerings Reata brought in $281m and Intellia grossed $175m.
Orladeyo is the first oral prophylactic approved in the US for hereditary angioedema, with Japan and EU approvals expected to follow. Pricing of $485,000 a year undercuts segment leader.